Daily Anesthesiology Research Analysis
Three anesthesiology-relevant studies stand out today: consensus guidelines standardize preoperative cardiovascular assessment for liver transplantation; a double-blind RCT shows liposomal bupivacaine in thoracic paravertebral block improves late-phase analgesia and reduces early opioid use after thoracoscopic lung surgery; and a randomized human endotoxemia study finds plasma resuscitation reduces leukocyte responses but does not prevent endothelial glycocalyx shedding versus balanced crystallo
Summary
Three anesthesiology-relevant studies stand out today: consensus guidelines standardize preoperative cardiovascular assessment for liver transplantation; a double-blind RCT shows liposomal bupivacaine in thoracic paravertebral block improves late-phase analgesia and reduces early opioid use after thoracoscopic lung surgery; and a randomized human endotoxemia study finds plasma resuscitation reduces leukocyte responses but does not prevent endothelial glycocalyx shedding versus balanced crystalloid.
Research Themes
- Perioperative cardiovascular risk stratification in liver transplantation
- Regional anesthesia formulations and chronic pain prevention
- Fluid resuscitation effects on endothelial biology in systemic inflammation
Selected Articles
1. International Liver Transplantation Society/Liver Intensive Care Group of Europe guidelines for cardiovascular assessment before liver transplantation.
An international expert panel issued evidence-graded guidelines for preoperative cardiovascular assessment in liver transplantation candidates, delivering seven strong and six conditional recommendations plus good-practice statements. The guidance aims to standardize risk stratification and testing to reduce perioperative cardiac morbidity and mortality.
Impact: These society-endorsed, GRADE-based recommendations provide a unified framework likely to influence perioperative evaluation pathways for a high-risk surgical population.
Clinical Implications: Anesthesiologists and transplant teams can adopt standardized, evidence-graded testing and optimization pathways to identify coronary disease, ventricular dysfunction, pulmonary hypertension, and other risks prior to liver transplantation, potentially improving outcomes and resource utilization.
Key Findings
- 24 experts developed preoperative cardiovascular assessment guidelines for liver transplantation using GRADE.
- Seven strong and six conditional recommendations were issued, plus multiple good-practice statements.
- 100% agreement across all recommendations after two rounds of deliberation.
Methodological Strengths
- Evidence appraisal via GRADE with transparent strength-of-recommendation grading
- Formal consensus process with complete agreement among panelists
Limitations
- Several recommendations rely on low to very low quality evidence
- Guideline statements lack prospective validation in external cohorts
Future Directions: Prospective validation of the recommended algorithms, integration of biomarkers and advanced imaging, and assessment of implementation impact on outcomes and costs.
Cardiovascular disease is the leading cause of morbidity and mortality among liver transplantation (LT) recipients. A panel of 24 experts from the International Liver Transplantation Society and the Liver Intensive Care Group of Europe convened to develop guidelines for preoperative cardiovascular assessment of LT candidates. The panel identified 7 areas required for standard cardiovascular preoperative assessment. Quality of evidence was evaluated using the Grading of Recommendations Assessment, Development, and Evaluation approach. Strong or conditional recommendations were provided according to the overall level of evidence. Good practice statements were provided for recommendations with only low to very low quality of evidence. After 2 rounds of deliberations, the panel provided 7 strong (high level of evidence, grade 1 ±) recommendations and 6 conditional (low level of evidence, grade 2 ±) recommendations for cardiovascular evaluation before LT. Seven recommendations were based on good practice statements because of a very low level of evidence. Agreement between panelists was reached for 100% of recommendations. Several recommendations are made to improve a candidate's cardiovascular assessment before LT.
2. Effect of Liposomal Bupivacaine for Preoperative Thoracic Paravertebral Blockade on Postoperative Pain Following Video-Assisted Thoracoscopic Lung Surgery: A Prospective, Double-Blind, Randomized Controlled Trial.
In 60 thoracoscopic lung surgery patients, liposomal bupivacaine for TPVB improved cough-related pain at 72 hours, reduced opioid use from 12–72 hours, and lowered 1–3 month chronic pain scores versus ropivacaine, without differences in rest pain. Postoperative nausea and vomiting increased, highlighting the need for antiemetic strategies and cost consideration.
Impact: A well-designed double-blind RCT demonstrates delayed-phase analgesic and opioid-sparing benefits with potential implications for ERAS pathways in thoracic surgery.
Clinical Implications: Consider liposomal bupivacaine for TPVB in thoracoscopy to enhance late-phase analgesia and reduce opioids, while implementing proactive antiemetic prophylaxis and evaluating cost-effectiveness and patient selection.
Key Findings
- Lower 72-hour dynamic (cough) VAS with liposomal bupivacaine versus ropivacaine (2.37 ± 0.56 vs 3.10 ± 0.82; p < 0.001).
- Reduced NRS at 36 h and 72 h, decreased sufentanil use from 12–72 h, and fewer PCA demands at 72 h.
- Lower chronic pain scores at 1–3 months, but higher postoperative nausea and vomiting.
Methodological Strengths
- Prospective, double-blind, randomized controlled design
- Clinically relevant endpoints including dynamic pain, opioid use, and chronic pain follow-up
Limitations
- Single-center study with modest sample size
- Increased PONV and high drug cost; not powered for rare adverse events
Future Directions: Multicenter trials to confirm benefits, define optimal dosing/antiemetic protocols, and conduct economic and patient-selection analyses.
OBJECTIVES: To compare liposomal bupivacaine versus ropivacaine for acute and chronic pain management via preoperative thoracic paravertebral blockade (TPVB) in thoracoscopic lung resection. DESIGN: A prospective, double-blind, randomized controlled trial. SETTING: This study was conducted in a single medical center. PARTICIPANTS: Sixty adults scheduled for elective thoracoscopic lung resection. INTERVENTIONS: Preoperative TPVB was performed with liposomal bupivacaine or ropivacaine. MEASUREMENTS: The primary outcome was the visual analogue scale (VAS) score during rest and dynamic within 72 hours postoperatively. Secondary outcomes included numerical rating scale (NRS) score, opioid consumption, patient-controlled analgesia demands, recovery quality, complications, and chronic pain incidence within 6 months postoperatively. MAIN RESULTS: The liposomal bupivacaine group demonstrated significantly lower dynamic cough VAS scores compared to the ropivacaine group at 72 h postoperatively (2.37 ± 0.56 v 3.10 ± 0.82, p < 0.001). Concomitantly, this group showed reduced NRS scores at 36 h and 72 h, decreased sufentanil consumption from 12 to 72 h, fewer patient-controlled analgesia demands at 72 h, and lower chronic pain scores at 1-3 months postoperatively. However, liposomal bupivacaine was associated with a higher incidence of postoperative nausea and vomiting (p < 0.05). No significant intergroup differences were observed in rest VAS scores, recovery quality, or other complications (all p > 0.05). CONCLUSIONS: Liposomal bupivacaine provided early analgesia comparable to ropivacaine in TPVB for thoracoscopic surgery, but delivered distinct delayed-phase benefits: superior cough-pain control at 72 h, reduced chronic pain scores at 1-3 months, and sustained opioid-sparing effects from 12 to 72 h postoperatively. These advantages support Enhanced Recovery After Surgery goals, though their use must be balanced against a higher postoperative nausea and vomiting incidence and substantial cost. Future implementation requires targeted antiemetic protocols and cost-benefit analyses for high-risk cohorts.
3. The effects of balanced crystalloid versus plasma on endothelial injury, systemic inflammation, and coagulation in experimental endotoxaemia: a randomised human volunteer study.
In a randomized human endotoxemia model, plasma reduced leukocyte and neutrophil counts versus equal-volume balanced crystalloid but did not decrease glycocalyx shedding (syndecan-1), challenging the assumption that plasma preserves endothelial glycocalyx integrity acutely.
Impact: The study provides mechanistic, randomized human data relevant to fluid choice in early systemic inflammation, a central issue in perioperative and critical care.
Clinical Implications: Plasma resuscitation may modulate inflammatory cell responses but should not be assumed to protect the endothelial glycocalyx in early endotoxemia; fluid selection should consider goals beyond presumed endothelial protection.
Key Findings
- Plasma resuscitation reduced leukocyte and neutrophil counts versus balanced crystalloid in human endotoxemia.
- Endothelial injury markers (e.g., syndecan-1) increased after LPS; plasma did not attenuate glycocalyx shedding compared with crystalloid.
- Findings challenge the hypothesis that plasma universally protects the glycocalyx during early systemic inflammation.
Methodological Strengths
- Randomized human volunteer model of endotoxemia
- Objective biomarker assessment of endothelial injury and inflammatory response
Limitations
- Small sample size of healthy male volunteers limits generalizability
- Short-term measurements without clinical outcomes
Future Directions: Larger, patient-centered trials to assess endothelial outcomes and clinical endpoints, and exploration of combined strategies targeting inflammation and endothelial protection.
BACKGROUND: During shock, neutrophil-mediated glycocalyx degradation can lead to exposure of the procoagulant endothelial surface and consequent organ injury. Resuscitation using crystalloid fluids may augment this endothelial damage, while resuscitation using plasma may preserve glycocalyx health. We hypothesised that resuscitation with plasma would preserve glycocalyx integrity by reducing inflammation, glycocalyx shedding, and dyscoagulation in a controlled model of systemic inflammation in human volunteers. METHODS: Twelve healthy male volunteers were injected with 2 ng kg RESULTS: LPS induced a systemic inflammatory response, accompanied by endothelial injury as indicated by increased levels of syndecan-1 (median increase: 2920-4430 pg ml CONCLUSIONS: In human endotoxaemia, plasma resuscitation reduced leucocyte and neutrophil levels but did not reduce glycocalyx degradation, when compared with equal volume resuscitation with a balanced crystalloid solution.